4-氯-5-氟-2-硝基苯甲醛 | 184843-93-4

• 物质功能分类: 医药中间体 - 原料药中间体
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-氯-5-氟-2-硝基苯甲醛
• 英文名称: 4-chloro-5-fluoro-2-nitrobenzaldehyde
• CAS: 184843-93-4
• 化学式: C₇H₃ClFNO₃
• 分子量: 203.557
• InChiKey: WYMZXNRXRADFTH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  62.9
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-氯-5-氟-2-硝基苯甲醛 以85的产率得到(+/-)-methyl 2-[(4-chloro-5-fluoro-2-nitrophenyl)hydroxymethyl]acrylate
  参考文献：
  名称：

  Compounds having antibacterial activity, process for their preparation and pharmaceutical compositions containing them

  摘要：

  公开号：

  EP0155006B1
• 作为产物：
  描述：

  4-氯-3-氟苯甲醛 在 硫酸 、 硝酸 作用下， 以93%的产率得到4-氯-5-氟-2-硝基苯甲醛
  参考文献：
  名称：

  Mechanism and synthesis of pharmacologically active quinolones from Morita–Baylis–Hillman adducts

  摘要：

  The synthesis of quinolones from Morita-Baylis-Hillman (MBH) adducts is reported. The quinolone skeleton is formed via a TFA-mediated cyclization of the MBH adduct, and a mechanism study using ESI (+)-MS(/MS) has indicated the role played by TFA in this key reaction step. The total syntheses of Norfloxacin and a benzyl quinolone carboxylic acid (BQCA) derivative are described. Norfloxacin is a fluoroquinolonic antibacterial drug whereas BQCA is M-1 receptor positive allosteric modulator and seem to provide access to new potential drugs for Alzheimer disease, pain, and sleep disorders. The syntheses of these two important quinolones exemplify the versatility and potentiality of the approach. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2010.04.018

文献信息

• METHOD FOR PRODUCING 2-AMINO-SUBSTITUTED BENZALDEHYDE COMPOUND
  申请人：Nippon Soda Co., Ltd.

  公开号：US20170226046A1

  公开（公告）日：2017-08-10

  The present invention provides a method for producing a benzaldehyde in which an amino group is bonded in the 2 position, a halogeno group or an alkoxy group is bonded in the 3 position, and a hydrogen atom, an alkyl group, a halogeno group, an alkoxy group, or a cyano group is bonded independently in each of the 4, 5, and 6 positions, the method including: preparing a benzaldehyde in which a halogeno group or an alkoxy group is bonded in the 3 position, a hydrogen atom is bonded in the 2 position, and a hydrogen atom, an alkyl group, a halogeno group, an alkoxy group, or a cyano group is bonded independently in each of the 4, 5, and 6 positions so that a lithiation reaction is most active at the 2 position; acetal-protecting a formyl group in the benzaldehyde; sequentially performing lithiation, azidation, and amination of the 2 position; and the performing acetal deportection.

  本发明提供了一种生产苯甲醛的方法，其中氨基与2位键合，卤素基或烷氧基与3位键合，氢原子、烷基、卤素基、烷氧基或氰基分别与4、5和6位键合，所述方法包括：制备苯甲醛，其中卤素基或烷氧基与3位键合，氢原子与2位键合，氢原子、烷基、卤素基、烷氧基或氰基分别与4、5和6位键合，以使锂化反应在2位最活跃；对苯甲醛中的甲酰基进行缩醛保护；顺序进行2位的锂化、叠氮化和胺化；然后进行缩醛去保护。
• [EN] MACROCYCLIC QUINAZOLINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS<br/>[FR] DERIVES DE QUINAZOLINE MACROCYCLIQUE UTILISES COMME AGENTS ANTIPROLIFERATIFS
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2004105765A1

  公开（公告）日：2004-12-09

  The present invention concerns the compounds of formula (I) the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein Z represents O, CH2, NH or S; in particular Z represents NH; Y represents -C3-9alkyl-, -C3-9alkenyl-, -C3-9alkynyl-, -C3-7alkyl-CO-NH- optionally substituted with amino, mono- or di(C1-4alkyl)amino or C1-4 alkyloxycarbonylamino-, -C3-7alkenyl-CO-NH- optionally substituted with amino, mono- or di(C1-4alkyl)amino- or C1-4alkyloxycarbonylamino-, C1-5alkyl-oxy-C1-5alkyl-, -C1-5alkyl NR13-, -C1-5alkyl-, -C1-5alkyl-NR14-CO-C1-5alkyl-, -C1-5alkyl-CO NR15-C1-5alkyl-, -C1-6alkyl-CO-NH-, -C1-6alkyl-NH-CO-, -C1-3alkyl-NH-CS-Het20-, -C1-3alkyl-NH-CO-Het20-, -C1-2alkyl-CO-Het21-CO-, -Het22-CH2-CO-NH-C1-3alkyl-, -CO-NH-C1-6alkyl-, -NH-CO-C1-6alkyl-, -CO-C1-7alkyl-, -C1-7alkyl-CO-, -C1-6alkyl-CO-C1-6alkyl-, -C1-2alkyl-NH-CO-CR16R17-NH-, -C1-2alkyl-CO-NH-CR18R19-CO-, -C1-2alkyl-CO-NR20-C1-3alkyl-CO-, C1-2alkyl-NR21-CH2-CO-NH-C1-3alkyl-, or -NR22-CO-C1-3alkyl-NH-; X1 represents a direct bond, O or -O-C1-2alkyl-, CO, -CO-C1-2alkyl-, NR11, -NR11-C1-2alkyl-, CH2-, -O-N=CH- or -C1-2alkyl-; X2 represents a direct bond, O, -O-C1-2alkyl-, CO, -CO-C1-2alkyl-, NR12, -NR12-C1-2alkyl-, -CH2-, -O-N=CH- or -C1-2alkyl-. The growth inhibitory effect anti-tumour activity of the present compounds has been demonstrated in vitro, in enzymatic assays on the receptor tyrosine kinase EGFR.

  本发明涉及公式（I）的化合物，其N-氧化物形式，药用可接受的加合物盐及其立体化异构形式，其中Z代表O、CH2、NH或S；特别是Z代表NH；Y代表-C3-9烷基，-C3-9烯基，-C3-9炔基，-C3-7烷基-CO-NH-（可选择地被氨基，单或双（C1-4烷基）氨基或C1-4烷氧羰氨基取代），-C3-7烯基-CO-NH-（可选择地被氨基，单或双（C1-4烷基）氨基或C1-4烷氧羰氨基取代），C1-5烷氧基-C1-5烷基，-C1-5烷基-NR13-，-C1-5烷基，-C1-5烷基-NR14-CO-C1-5烷基，-C1-5烷基-CO NR15-C1-5烷基，-C1-6烷基-CO-NH-，-C1-6烷基-NH-CO-，-C1-3烷基-NH-CS-Het20-，-C1-3烷基-NH-CO-Het20-，-C1-2烷基-CO-Het21-CO-，-Het22-CH2-CO-NH-C1-3烷基-，-CO-NH-C1-6烷基-，-NH-CO-C1-6烷基-，-CO-C1-7烷基-，-C1-7烷基-CO-，-C1-6烷基-CO-C1-6烷基-，-C1-2烷基-NH-CO-CR16R17-NH-，-C1-2烷基-CO-NH-CR18R19-CO-，-C1-2烷基-CO-NR20-C1-3烷基-CO-，C1-2烷基-NR21-CH2-CO-NH-C1-3烷基-，或-NR22-CO-C1-3烷基-NH-；X1代表直接键，O或-O-C1-2烷基-，CO，-CO-C1-2烷基-，NR11，-NR11-C1-2烷基-，CH2-，-O-N=CH-或-C1-2烷基-；X2代表直接键，O，-O-C1-2烷基-，CO，-CO-C1-2烷基-，NR12，-NR12-C1-2烷基-，-CH2-，-O-N=CH-或-C1-2烷基-。本发明化合物的生长抑制效应和抗肿瘤活性已在体外实验中，在EGFR受体酪氨酸激酶的酶促活性测定中得到证明。
• [EN] AZETIDINE AND PIPERIDINE COMPOUNDS USEFUL AS PDE10 INHIBITORS<br/>[FR] COMPOSÉS D'AZÉTIDINE ET DE PIPÉRIDINE UTILES COMME INHIBITEURS DE PDE10
  申请人：AMGEN INC

  公开号：WO2013188724A1

  公开（公告）日：2013-12-19

  Azetidine and piperidine compounds of formula (I) as defined in the specification, compositions containing them, and processes for preparing such compounds and intermediates thereof. Provided herein also are methods of treating cognitive disorders or diseases treatable by inhibition of PDE10, such as Huntington's Disease, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.

  Azetidine和piperidine化合物的化学式（I），包含它们的组合物，以及制备这些化合物和其中间体的过程。本文还提供了治疗认知障碍或通过抑制PDE10可治疗的疾病的方法，如亨廷顿病、精神分裂症、双相情感障碍、强迫症等。
• [EN] 3-CYANO-QUINOLINE DERIVATIVES WITH ANTIPROLIFERATIVE ACTIVITY<br/>[FR] DERIVES DE 3-CYANO-QUINOLINE A ACTIVITE ANTIPROLIFERATIVE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2005058318A1

  公开（公告）日：2005-06-30

  The present invention concerns the compounds of formula (I) the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof. Compounds of formula (I) inhibit tyrosine kinase enzymes.

  本发明涉及式(I)的化合物，其N-氧化物形式，药用可接受的加合盐以及其立体化异构体形式。式(I)的化合物抑制酪氨酸激酶酶。
• Synthetic Studies on Indolocarbazoles: A Facile Synthesis of Staurosporinone Analogues
  作者：Potharaju Raju、Ganesan Gobi Rajeshwaran、Arasambattu K. Mohanakrishnan

  DOI：10.1002/ejoc.201500939

  日期：2015.11

  Synthesis of indolocarbazoles was achieved through thermal electrocyclization followed by triethyl phosphite-mediated nitrene insertion reactions. Total synthesis of staurosporinone analogues was achieved from commercially available 2-methylindole. The CDK5/p25 kinase inhibition potential of some representative staurosporinone analogues was explored by using the TRFRET kinase assay.

  通过热电环化和亚磷酸三乙酯介导的氮烯插入反应合成吲哚并咔唑。staurosporinone 类似物的全合成是从市售的 2-甲基吲哚中实现的。通过使用 TRFRET 激酶测定探索了一些代表性星形孢菌素类似物的 CDK5/p25 激酶抑制潜力。